Evidence map›Paper›PMID 42635953›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Single-Dose TACE-Like Injection of Sustained-Release Panobinostat/IL-12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models.

Hongzhe Yu, Ling Li, Sachin S Surwase, Xin Ming M Zhou, Hongtao Qian, Joel C Sunshine, Florin M Selaru, Jordan J Green

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongzhe Yu *Department of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins Translational ImmunoEngineering Center, and the Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland, USA.
Ling Li *Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-4498-9466
Sachin S SurwaseDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins Translational ImmunoEngineering Center, and the Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland, USA.
Xin Ming M ZhouDepartment of Dermatology, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0009-0003-1020-068X
Hongtao QianDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Joel C SunshineDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins Translational ImmunoEngineering Center, and the Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-9987-6712
Florin M SelaruDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins Translational ImmunoEngineering Center, and the Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-7990-8238
Jordan J GreenDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins Translational ImmunoEngineering Center, and the Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-4176-3808

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jordan Green, JONATHAN P SCHNECK · 2019 to 2026
$11.5M
Gene Delivery Nanoparticles to Treat GlioblastomaR01CA228133 · NCI · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2019 to 2023
$1.9M
Atran Family FoundationNCI NIH HHS P30 CA006973NCI NIH HHS R01 CA228133NIBIB NIH HHS P41 EB024495NIBIB NIH HHS P41 EB028239NIH HHS P30CA006973NIH HHS P41EB024495NIH HHS P41EB028239NIH HHS R01CA228133
6 · The paper itself

Abstract

BACKGROUND &

aimsPrimary liver cancer is the third leading cause of cancer death worldwide, and about 70% of hepatocellular carcinomas (HCCs) do not respond to systemic immunotherapies. Transarterial chemoembolization (TACE) remains standard treatment for intermediate-stage HCC, but long-term survival is poor. We aimed to develop a polymeric TACE-like platform to sensitize liver cancer to checkpoint inhibitors by enabling sustained co-delivery of panobinostat and IL-12.

methodsPatient-derived liver cancer organoids were used to screen drugs and identify panobinostat as a cytotoxic agent. We then formulated sustained-release microparticles from anionic poly(lactic-co-glycolic acid) (PLGA) and cationic poly(beta-amino ester) (PBAE) for combined delivery of panobinostat and IL-12, and tested the system in three liver cancer models.

resultsThe microparticles achieved tumor-specific retention and sustained release for two weeks following a single intratumoral or intrahepatic arterial injection. This led to tumor inhibition and prolonged survival in orthotopic liver cancer models. Mechanistically, treatment promoted tertiary lymphoid structure formation, increased infiltration of immune cells, and elevated pro-inflammatory cytokines, triggering innate and adaptive antitumor immune responses.

conclusionsA PLGA/PBAE sustained-release microparticle platform was successfully developed for TACE-like co-delivery of panobinostat and IL-12. This combined chemoimmunotherapy strategy shows promise for overcoming immune suppression and improving liver cancer treatment.

Indexed as

HCCIL12panobinostatPLGA/PBAE microparticleTACE

Identifiers

PMID42635953
PMCPMC13502277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.